Ilduara Pintos Pascual

Ilduara Pintos Pascual

Auto-generated profile, based on publicly available information

Ilduara Pintos Pascual

Servicio de Medicina Interna. Hospital Universitario Puerta de Hierro. Majadahonda. Madrid. España

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
CACristina Avendaño-Solá
Cristina Avendaño-Solá
ARAntonio Ramos-Martínez
Antonio Ramos-Martínez
EMElena Muñez-Rubio
Elena Muñez-Rubio
BRBELEN RUIZ-ANTORÁN
BELEN RUIZ-ANTORÁN
RRRosa Malo de Molina Ruiz
Rosa Malo de Molina Ruiz
RDRafael Duarte
Rafael Duarte
BACKGROUND. Passive immunotherapy with convalescent plasma (CP) is a potential treatment for COVID-19. Evidence from controlled clinical trials is inconclusive. METHODS. We conducted a randomized, open-label, controlled clinical trial at 27 hospitals in Spain. Patients had to be admitted for COVID-19 pneumonia within 7 days from symptom onset and not on mechanical ventilation or high-flow oxygen devices. Patients were randomized 1:1 to treatment with CP in addition to standard of care (SOC) or to the control arm receiving only SOC. The primary endpoint was the proportion of patients in categories 5 (noninvasive ventilation or high-flow oxygen), 6 (invasive mechanical ventilation or extracorporeal membrane oxygenation [ECMO]), or 7 (death) at 14 days. Primary analysis was performed in the intention-to-treat population. RESULTS. Between April 4, 2020, and February 5, 2021, 350 patients were randomly assigned to either CP (n = 179) or SOC (n = 171). At 14 days, proportion of patients in categories 5, 6, or 7 was 11.7% in the CP group versus 16.4% in the control group (P = 0.205). The difference was greater at 28 days, with 8.4% of patients in categories 5–7 in the CP group versus 17.0% in the control group (P = 0.021). The difference in overall survival did not reach statistical significance (HR 0.46, 95% CI 0.19–1.14, log-rank P = 0.087). CONCLUSION. CP showed a significant benefit in preventing progression to noninvasive ventilation or high-flow oxygen, invasive mechanical ventilation or ECMO, or death at 28 days. The effect on the predefined primary endpoint at 14 days and the effect on overall survival were not statistically significant. TRIAL REGISTRATION. Clinicaltrials.gov, NCT04345523. FUNDING. Government of Spain, Instituto de Salud Carlos III.

27 April 2022 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
ARAntonio Ramos-Martínez
Antonio Ramos-Martínez
IPIlduara Pintos-Pascual
Ilduara Pintos-Pascual
Jesus GuineaJesus Guinea
Jesus Guinea
AGAndrea Gutierrez-Villanueva
Andrea Gutierrez-Villanueva
EGEdith Gutiérrez-Abreu
Edith Gutiérrez-Abreu
Ana Fernández-CruzAna Fernández-Cruz
Ana Fernández-Cruz
Severely ill COVID-19 patients are at high risk of nosocomial infections. The aim of the study was to describe the characteristics of candidemia during the pre-pandemic period (January 2019–February 2020) compared to the pandemic period (March 2020–September 2021). Antifungal susceptibilities were assessed using the EUCAST E.Def 7.3.2 broth dilution method. Fluconazole-resistant C. parapsilosis isolates (FRCP) were studied for sequencing of the ERG11 gene. The incidence of candidemia and C. parapsilosis bloodstream infection increased significantly in the pandemic period (p = 0.021). ICU admission, mechanical ventilation, parenteral nutrition and corticosteroids administration were more frequent in patients with candidemia who had been admitted due to COVID-19. Fifteen cases of FRCP fungemia were detected. The first case was recorded 10 months before the pandemic in a patient transferred from another hospital. The incidence of FRCP in patients admitted for COVID-19 was 1.34 and 0.16 in all other patients (p < 0.001). ICU admission, previous Candida spp. colonization, arterial catheter use, parenteral nutrition and renal function replacement therapy were more frequent in patients with candidemia due to FRCP. All FRCP isolates showed the Y132F mutation. In conclusion, the incidence of candidemia experienced an increase during the COVID-19 pandemic and FRCP fungemia was more frequent in patients admitted due to COVID-19.

23 April 2021 in Medicine
Verified
Journal Article
Open access
VMVictor Moreno-Torres
Victor Moreno-Torres
SFSara de la Fuente
Sara de la Fuente
PMPatricia Mills
Patricia Mills
AMAlejandro Muñoz
Alejandro Muñoz
EMElena Muñez
Elena Muñez
CMCarmen de Mendoza
Carmen de Mendoza
Spain is one of the European countries most largely affected by COVID-19, being Madrid the epicenter. A good knowledge of the main features of hospitalized patients during the complete lockdown should improve the management of new COVID-19 surges. All patients hospitalized at one large tertiary hospital in Madrid for suspected COVID-19 pneumonia from March 1 to May 31 were retrospectively identified. A total of 1752 patients were admitted with suspected pneumonia due to SARS-CoV-2 infection during the 3-month study period. The peak of daily admissions (n = 84) was reached on March 24, whereas the maximal cumulative number of hospitalized patients (n = 626) occurred on March 30. Overall, 85.3% had a positive PCR test for SARS-CoV-2 at least once during admission. Their median age was 65 (54–77) and 59.9% were male. The median length of hospitalization was of 7 (4–13) days. Roughly 6.5% were admitted at the intensive care unit. Death occurred in 242 (13.8%). Overall, 75% of deaths occurred in patients older than 75 years-old. It was 38.2% in patients hospitalized older than 80 years-old versus 2.2% in patients younger than 60 years-old (p < 0.001). Up to 94 (38.8%) of deceased patients had been transferred from nursing homes. The median Charlson co-morbidity score was 6 in deceased patients. The in-hospital mortality rate during the first wave of COVID-19 in Madrid was 14%. It was largely driven by older age, the presence of underlying chronic conditions (≥2) and living at nursing homes.

6 November 2024 in Antioxidants
Verified
Journal Article
Open access
PDF file
ASAmanda Cuevas Sierra
Amanda Cuevas Sierra
VOVíctor de la O
Víctor de la O
Andrea Higuera GómezAndrea Higuera Gómez
Andrea Higuera Gómez
LCLourdes Chero-Sandoval
Lourdes Chero-Sandoval
BCBegoña de Cuevillas
Begoña de Cuevillas
JMJ. Alfredo Martinez
J. Alfredo Martinez
Chronic viral inflammation is associated with oxidative stress and changes in gut microbiota. The Mediterranean diet (MD), with recognized anti-inflammatory and antioxidant properties, modulates gut microorganisms, specifically on the interaction between extra virgin olive oil, a key component of the MD with well-documented antioxidant effects. This study investigated the influence of adherence to MD and antioxidant-rich foods (extra virgin olive oil) on biochemical, inflammatory, and microbiota profiles in patients with chronic inflammation defined as a prolonged inflammatory response due to immune dysregulation following the acute phase of the viral infection. Participants were classified into low (n = 54) and high (n = 134) MD adherence groups (cut-off of 7 points based on previous studies utilizing the same threshold in the assessment of MD adherence). Gut microbiota was sequenced using the 16S technique, and the adherence to MD was assessed using a validated questionnaire for a Spanish population. High adherence to the MD was linked to significant improvements in inflammatory and oxidative stress markers, including reductions in LDL-cholesterol, glucose, and lactate dehydrogenase (LDH) levels, an indicative of redox balance, as well as a significant higher consumption of antioxidant foods. Moreover, gut microbiota analysis revealed distinct compositional shifts and a lower abundance of the Oscillibacter genus in the high adherence group. Notably, a significant interaction was observed between MD adherence and extra virgin olive oil consumption, with Oscillibacter abundance influencing LDH levels, suggesting that the MD antioxidant properties may modulate inflammation through gut microbiota-mediated mechanisms. These findings provide new evidence that adherence to the Mediterranean diet can reduce inflammatory markers in patients with long-COVID-19, a population that has not been extensively studied, while also highlighting the potential role of the bacterial genus Oscillibacter in modulating this effect.

22 January 2022 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
VMVictor Moreno-Torres
Victor Moreno-Torres
AMAlejandro Muñoz-Serrano
Alejandro Muñoz-Serrano
JCJorge Calderón-Parra
Jorge Calderón-Parra
PMPatricia Mills-Sánchez
Patricia Mills-Sánchez
IPIlduara Pintos-Pascual
Ilduara Pintos-Pascual
CMCarmen de Mendoza
Carmen de Mendoza
The aim of the study was to analyze the mortality and characteristics of deceased patients with COVID-19 during the first year of the pandemic. All admissions owing to COVID-19 at a tertiary hospital in Madrid were analyzed. Three waves were considered: March 2020 to June 2020, July 2020 to November 2020, and December 2020 to April 2021. A total of 3,676 patients were identified. Among inpatients, no differences regarding age, sex, length of admission, or mortality were found between the 3 waves (p >0.05). The overall mortality rate was 12.9%. Among deceased patients, the median age was 82 years and the median Charlson Comorbidity Index was 6. Considering the main predictors for mortality by COVID-19 (age, sex, and concomitant comorbidities), only patients with previous lung disease were more prevalent in the third period (p <0.01). Finally, higher intensive care unit admission rates, a lower rate of patients coming from nursing homes, and a lower rate of patients with dementia were noted in the third period (p <0.05) among deceased patients. One year after the onset of the pandemic, the mortality rate of hospitalized patients and the profile of non-survivors have not changed significantly. In the absence of vaccine benefits, advanced age and multiple pathologies are uniform characteristics of non-survivors.

24 March 2020 in Revista Española de Quimioterapia
Verified
Journal Article
Open access
IPI Pintos-Pascual
I Pintos-Pascual
MCM Cantero-Caballero
M Cantero-Caballero
ERE Muñez Rubio
E Muñez Rubio
ISI Sánchez-Romero
I Sánchez-Romero
AAA Asensio-Vegas
A Asensio-Vegas
ARA Ramos-Martínez
A Ramos-Martínez
To describe the epidemiology of Enterobacterales producing carbapenemases (EPC) in a tertiary hospital. A retrospective observational study, all patients with a positive sample for EPC treated in hospitalization or in the Emergency Department were included, between January 1, 2014 and December 31, 2016. A total of 272 patients (316 samples) were included: 155 (57%) male. Mean age of 70.4 years (95% CI 68.2 -72.7). Mean Charlson index was 3.6 (95% CI 3.4-3.8). In 63.2% the acquisition was nosocomial, in 35.3% it was health-care associated (HA). 55.1% presented infection, the most frequent infection was urinary tract infection (UTI) (58.7%). The most frequent species were Klebsiella pneumoniae (62.7%) and Enterobacter cloacae (10.1%). The most frequent types of carbapenemase were OXA-48 (53.8%) and VIM (43%). The nosocomial acquisition was associated with the male gender, transplantation, immunosuppression, admission to the Intensive Care Unit (ICU) or surgical service, prior antibiotic treatment, Enterobacter, VIM, respiratory and intra-abdominal infections. The HA acquisition was associated with age and comorbidity, nursery home origin, bladder catheterization, greater number of outpatient procedures, previous hospital admission, K. pneumoniae and E. coli, OXA-48, coproduction of extended spectrum betalactamases, UTI and sepsis. Patients who acquire EPC in nursery homes frequently have an infection. Patients with nosocomial acqui-sition are colonized by EPC in the ICU, in relation to invasive procedures and transplantation. This population has a higher mortality due to developing respiratory infections by EPC.